France-based bio-pharmaceutical company Hybrigenics has appointed Dr Alain Munoz to its board of directors.
Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems, and will chair the clinical advisory board.
He has over 20 years' experience in the pharmaceutical industry at senior management level with the Sanofi Group as R&D vice-president and the French pharmaceutical company Fournier as VP of R&D and business development, subsequently becoming senior VP of the pharmaceutical division.
As well as his position at Hybrigenics, Dr Munoz is also a board member of several biotechnology companies including Novagali Pharma and Zealand Pharma.
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...